Recombinant Cynomolgus DNAM-1 / CD226 Protein, His Tag, 100 µg

Background
DNAX accessory molecule 1 (DNAM-1), a single-pass type I membrane protein, is also known as CD226 antigen and platelet and T cell activation antigen 1 (PTA1), which contains 2 Ig-like C2-type (immunoglobulin-like) domains. DNAM-1 is a ~65 kDa glycoprotein expressed on the surface of natural killer cells, platelets, monocytes and a subset of T cells. DNAM-1 mediates cellular adhesion to other cells bearing its ligands, CD112 and CD155, and cross-linking DNAM-1 with antibodies causes cellular activation. Furthermore, DNAM-1 can interact with PVR and PVRL2.

Source
Recombinant Cynomolgus DNAM-1, His Tag (DN1-C52H9) is expressed from human 293 cells (HEK293). It contains AA Glu 19 - Phe 252 (Accession # A0A2K5W1Z6-1).
Predicted N-terminus: Glu 19

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 28.5 kDa. The protein migrates as 40-55 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>90% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20^°C to -70^°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1)  "NK Receptors Replace CD28 As the Dominant Source of Signal 2 for Cognate Recognition of Cancer Cells by TAA-specific Effector CD8+ T Cells"
Dong, Obermajer, Tsuji et al
Res Sq (2023)
(2)  "Dysregulation of DNAM-1-Mediated NK Cell Anti-Cancer Responses in the Tumor Microenvironment"
Paolini, Molfetta
Cancers (Basel) (2023) 15 (18)
(3)  "Activation of CD8+ T Cells in COPD Lung"
Villaseñor-Altamirano, Jain, Jeong et al
Am J Respir Crit Care Med (2023)
Showing 1-3 of 434 papers.